12505 related articles for article (PubMed ID: 11587361)
1. Histone deacetylase as a new target for cancer chemotherapy.
Yoshida M; Furumai R; Nishiyama M; Komatsu Y; Nishino N; Horinouchi S
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S20-6. PubMed ID: 11587361
[TBL] [Abstract][Full Text] [Related]
2. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.
Furumai R; Komatsu Y; Nishino N; Khochbin S; Yoshida M; Horinouchi S
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):87-92. PubMed ID: 11134513
[TBL] [Abstract][Full Text] [Related]
3. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
[TBL] [Abstract][Full Text] [Related]
4. From discovery to the coming generation of histone deacetylase inhibitors.
Yoshida M; Matsuyama A; Komatsu Y; Nishino N
Curr Med Chem; 2003 Nov; 10(22):2351-8. PubMed ID: 14529478
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of histone deacetylase as new anticancer agents.
Jung M
Curr Med Chem; 2001 Oct; 8(12):1505-11. PubMed ID: 11562279
[TBL] [Abstract][Full Text] [Related]
6. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase.
Kim YB; Lee KH; Sugita K; Yoshida M; Horinouchi S
Oncogene; 1999 Apr; 18(15):2461-70. PubMed ID: 10229197
[TBL] [Abstract][Full Text] [Related]
7. Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export.
Yoshida M; Horinouchi S
Ann N Y Acad Sci; 1999; 886():23-36. PubMed ID: 10667200
[TBL] [Abstract][Full Text] [Related]
8. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
Chang J; Varghese DS; Gillam MC; Peyton M; Modi B; Schiltz RL; Girard L; Martinez ED
Br J Cancer; 2012 Jan; 106(1):116-25. PubMed ID: 22158273
[TBL] [Abstract][Full Text] [Related]
9. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S
J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976
[TBL] [Abstract][Full Text] [Related]
10. Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors.
Nishino N; Jose B; Shinta R; Kato T; Komatsu Y; Yoshida M
Bioorg Med Chem; 2004 Nov; 12(22):5777-84. PubMed ID: 15498654
[TBL] [Abstract][Full Text] [Related]
11. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.
Nakajima H; Kim YB; Terano H; Yoshida M; Horinouchi S
Exp Cell Res; 1998 May; 241(1):126-33. PubMed ID: 9633520
[TBL] [Abstract][Full Text] [Related]
12. Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors.
Varghese S; Gupta D; Baran T; Jiemjit A; Gore SD; Casero RA; Woster PM
J Med Chem; 2005 Oct; 48(20):6350-65. PubMed ID: 16190761
[TBL] [Abstract][Full Text] [Related]
13. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
Liao V; Liu T; Codd R
Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
[TBL] [Abstract][Full Text] [Related]
14. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
Vigushin DM; Ali S; Pace PE; Mirsaidi N; Ito K; Adcock I; Coombes RC
Clin Cancer Res; 2001 Apr; 7(4):971-6. PubMed ID: 11309348
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
Frønsdal K; Saatcioglu F
Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
Butler LM; Webb Y; Agus DB; Higgins B; Tolentino TR; Kutko MC; LaQuaglia MP; Drobnjak M; Cordon-Cardo C; Scher HI; Breslow R; Richon VM; Rifkind RA; Marks PA
Clin Cancer Res; 2001 Apr; 7(4):962-70. PubMed ID: 11309347
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells.
Kim YB; Ki SW; Yoshida M; Horinouchi S
J Antibiot (Tokyo); 2000 Oct; 53(10):1191-200. PubMed ID: 11132966
[TBL] [Abstract][Full Text] [Related]
20. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
Finnin MS; Donigian JR; Cohen A; Richon VM; Rifkind RA; Marks PA; Breslow R; Pavletich NP
Nature; 1999 Sep; 401(6749):188-93. PubMed ID: 10490031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
